Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curis Lifesciences's Enterprise Value is ₹892.7 Mil.
Curis Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹107.0 Mil. Therefore, Curis Lifesciences's EV-to-EBIT ratio for today is 8.34.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Curis Lifesciences's Enterprise Value is ₹892.7 Mil.
Curis Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹114.0 Mil. Therefore, Curis Lifesciences's EV-to-EBITDA ratio for today is 7.83.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Curis Lifesciences's Enterprise Value is ₹892.7 Mil.
Curis Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹601.6 Mil. Therefore, Curis Lifesciences's EV-to-Revenue ratio for today is 1.48.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Curis Lifesciences (NSE:CURIS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Curis Lifesciences's current Enterprise Value is ₹892.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹107.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Curis Lifesciences's current Enterprise Value is ₹892.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹114.0 Mil.
Curis Lifesciences's current Enterprise Value is ₹892.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹601.6 Mil.
Curis Lifesciences's current Enterprise Value is ₹892.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-17.6 Mil.
Curis Lifesciences's current Enterprise Value is ₹892.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-18.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Enterprise Value Related Terms
Curis Lifesciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Enterprise Value Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Enterprise Value
0.00
0.00
0.00
835.67
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Enterprise Value
0.00
0.00
0.00
835.67
NSE:CURIS vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Curis Lifesciences's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Enterprise Value of ₹892.7 Mil as of Jul. 15, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Curis Lifesciences and its competitors.
Is Curis Lifesciences' Enterprise Value too high?
Curis Lifesciences' current Enterprise Value is ₹892.7 Mil. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Enterprise Value compare to ZTS and UTHR?
Curis Lifesciences' Enterprise Value of ₹892.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Curis Lifesciences and its competitors. Curis Lifesciences's current Enterprise Value is ₹892.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Enterprise Value of ₹892.7 Mil. The current Enterprise Value is ₹892.7 Mil. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Enterprise Value is ₹892.7 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
